NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
NCT02319824 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes in Sarcoma. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 30 Jun 2015. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02319824 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 2 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Sarcoma |
| Drugs | Autologous NY-ESO-1-specific CD8-positive T Lymphocytes |
| Start | 31 Jan 2015 |
| Primary completion | 30 Jun 2015 |
| Last update posted | 5 Jul 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Seth Pollack
Fred Hutch/University of Washington Cancer Consortium
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutch/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02319824
Each answer restates registry values shown on this page.
What is NCT02319824?
NCT02319824 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes in Sarcoma.
Who leads NCT02319824?
The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.
Where does NCT02319824 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02319824 study?
The registered drug and biological interventions are Autologous NY-ESO-1-specific CD8-positive T Lymphocytes.
When did NCT02319824 end?
The registry lists a primary completion date of 30 Jun 2015. The sponsor last updated the record on 5 Jul 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.